Mentor Capital Retains Network 1 Financial Securities for Comprehensive Investment Banking Services

SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) today announced the engagement of Network 1 Financial Securities, Inc. to provide investment banking, investor relations and financial advisory services. Network 1 Financial Securities, Inc. is headquartered in Red Bank, New Jersey and is an independent full-service securities firm.

"We look forward to working with Mentor Capital on their compelling strategy to invest in cutting edge cancer immunotherapy companies. We believe we can help the Company position itself more effectively in the capital markets and facilitate additional portfolio opportunities due to our significant relationships in this area," commented Damon Testaverde, Managing Director for Network 1 Financial Securities, Inc.

Mentor Capital is focused on making investments in companies that are making breakthroughs in this new approach to fighting cancer known as immunotherapy. In July 2009, Mentor Capital created the first ever Cancer Immunotherapy Index to track the leading companies. In response to investor interest, in December 2009, Mentor Capital announced the actively managed Cancer Immunotherapy Index Fund. The CII Fund is the investment vehicle that will be actively managed to maximize shareholder returns.

Mentor Capital CEO, Chet Billingsley, said, "In depth medical science discussions with CI Index researchers has identified for us those CII Fund leaders moving toward FDA approvals that will not only change cancer treatments as we know them but should also produce significant gains. I believe that Network 1 Financial Securities' experienced team, will assist us in effectively implementing our corporate and financial plans to fund these immunotherapy companies."

About Cancer Immunotherapy:

In cancer immunotherapy the patient's own immune system is taught to recognize and identify cancer cells as if it were an invading microbe. Then, in the same fashion that the body dispatches the common germ, killer T-cells land on the cancer cell, perforate the cell membrane, inject enzymes to dissolve cell organs and finally send in granzynes to chop up the cancerous DNA. Instead of disfiguring surgeries, radiation or debilitating chemotherapy, patients undergoing treatment often feel like they have slight case of the flu.

Additional information on Mentor Capital plus listings and links to all Cancer Immunotherapy Index companies may be referenced from the company website:

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

    Source: Mentor Capital, Inc.